CEO of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) John Maraganore sold 74,000 shares of ALNY on 11/15/2017 at an average price of $126.86 a share. The total sale was $9.4 million.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes. Alnylam Pharmaceuticals Inc has a market cap of $11.82 billion; its shares were traded at around $127.51 with and P/S ratio of 161.43. Alnylam Pharmaceuticals Inc had annual average EBITDA growth of 18.10% over the past ten years.
CEO Recent Trades:
CEO John Maraganore sold 74,000 shares of ALNY stock on 11/15/2017 at the average price of $126.86. The price of the stock has increased by 0.51% since.
Directors and Officers Recent Trades:
Director Dennis A Ausiello sold 20,000 shares of ALNY stock on 11/02/2017 at the average price of $130. The price of the stock has decreased by 1.92% since.EVP, R&D Akshay Vaishnaw sold 33,666 shares of ALNY stock on 10/30/2017 at the average price of $121.46. The price of the stock has increased by 4.98% since.
For the complete insider trading history of ALNY, click here